• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Malignant Melanoma Drug Pipeline Capsule - 2012 Product Image

Global Malignant Melanoma Drug Pipeline Capsule - 2012

  • ID: 2011280
  • January 2012
  • Region: Global
  • 15 pages
  • Fore Pharma

Fore Pharma’s latest report ‘Global Malignant Melanoma Drug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global Malignant Melanoma drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including READ MORE >

1. Malignant Melanoma: Disease Definition
2. Malignant Melanoma Drug Pipeline Overview
3. Malignant Melanoma Phase 3 Clinical Trial Drug Pipeline Insights
4. Malignant Melanoma Phase 2 Clinical Trial Drug Pipeline Insights
5. Malignant Melanoma Phase 1 Clinical Trial Drug Pipeline Insights
6. Malignant Melanoma Preclinical Research Drug Pipeline Insights
7. Malignant Melanoma Drug Discovery Pipeline Insights
8. Geographic Landscape of Malignant Melanoma R&D Activities
8.1. Malignant Melanoma R&D Activities in North America
8.2. Malignant Melanoma R&D Activities in Europe
9. Licensing Activities / Partnerships in the Global Malignant Melanoma Drug Market
10. Research Methodology
Table 1: Malignant Melanoma Drug Pipeline: Phase 3 Clinical Trial Molecules
Table 2: Malignant Melanoma Drug Pipeline: Phase 2 Clinical Trial Molecules
Table 3: Malignant Melanoma Drug Pipeline: Phase 1 Clinical Trial Molecules
Table 4: Malignant Melanoma Drug Pipeline: Preclinical Research Molecules
Table 5: Malignant Melanoma R&D Activities by Geography
Table 6: Malignant Melanoma Drug Pipeline: North America
Table 7: Malignant Melanoma Drug Pipeline: Europe
Table 8: Malignant Melanoma Drug Pipeline: Licensing Activities
Figure 1 : Malignant Melanoma Drug Pipeline Molecules by Stages
Figure 2 : Malignant Melanoma R&D Activities by Geography

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos